GlassScriptPhysician profile
Fiona Hanly
NPI 1265749345
$10,515.14
in general payments reported to CMS, 2019-2025
35 companies · $3,669 in 2025
The $3,669 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,286 · 2022: $1,683 · 2023: $2,255 · 2024: $1,622 · 2025: $3,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,882 · Consulting Fee: $1,455 · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,882.39 |
| Consulting Fee | $1,455.00 |
| Education | $208.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,545.46 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,455.00 | 2025 | |
| Sun Pharmaceutical Industries INC. | $865.84 | 2021-2025 | Ilumya, Levulan Kerastick, Winlevi |
| Amgen INC. | $729.80 | 2021-2025 | Otezla, Enbrel, Otezla |
| Lilly USA, LLC | $563.90 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $503.17 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $474.94 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $447.99 | 2021-2025 | |
| Pfizer INC. | $438.31 | 2021-2025 | |
| Ucb, INC. | $391.22 | 2021-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $372.15 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $349.98 | 2021-2025 | Nemluvio, Aklief |
| Incyte Corporation | $280.53 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $249.55 | 2023-2025 | Tremfya, Simponi, Stelara |
| Leo Pharma INC. | $204.42 | 2021-2025 | Anzupgo, Adbry |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $202.22 | 2024-2025 | Sotyktu |
| Botanix Sb INC | $183.09 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $176.68 | 2021-2025 | Jublia |
| Dermavant Sciences, INC. | $169.93 | 2023-2024 | Vtama |
| Organon LLC | $166.18 | 2025 | Vtama |
| Kyowa Kirin, INC. | $161.85 | 2023-2025 | Poteligeo |
| Verrica Pharmaceuticals INC. | $95.97 | 2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.03 | 2023-2024 | Spevigo, Cyltezo |
| Almirall LLC | $81.39 | 2022-2025 | Seysara, Klisyri |
| Merck Sharp & Dohme LLC | $51.02 | 2023 | Keytruda |
| Mayne Pharma Commercial LLC | $48.28 | 2022-2025 | |
| Allergan, INC. | $40.09 | 2022 | |
| Currax Pharmaceuticals LLC | $32.60 | 2021 | |
| Mimedx Group, INC. | $30.20 | 2024 | |
| Biofrontera INC. | $27.65 | 2022 | |
| Vyne Pharmaceuticals INC. | $25.54 | 2021 | |
| Organogenesis INC. | $19.75 | 2023 | Puraply |
| Celltrion USA INC. | $17.72 | 2025 | Vegzelma |
| Epi Health, LLC | $12.87 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fiona Hanly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.